Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia Authors: Yi-Tong Li, Yu Li, Li-Na Wang, Li-Bin Huang Published: 2026 ABSTRACT BackgroundAcute lymphoblastic leukemia (ALL) is the most common malignant hematological disease in children. Patients with high-risk ALL have a poor prognosis, and allogeneic hematopoietic stem cell transplantation (HSCT) is one of the important treatment modalities. However, post-transplant relapse of the primary disease remains one of the leading causes of treatment failure, seriously affecting the long-term survival of patients. Donor lymphocyte infusion (DLI) has been shown to have some efficacy in preventing relapse in B-cell ALL after HSCT, while the use of blinatumomab for preventing post-transplant relapse in ALL remains under investigation. Moreover, the safety and efficacy of the combination regimen for this indication still need to be verified in larger patient cohorts. We herein report a single case of a child with high-risk ALL who received blinatumomab combined with prophylactic DLI to prevent relapse after HSCT, along with a brief review of the relevant literature.Case presentationA 5-year-old boy was diagnosed as ALL, early pro-B, KMT2A::USP2 fusion gene positive. After induction treatment with the SCCLG-ALL-2016 protocol, the minimal residual disease (MRD) by flow cytometry(FCM) and the quantitative PCR of KMT2A::USP2 fusion gene and NGS IGH remained continuous positive. The child received one cycle of blinatumomab, and the MRD by FCM and RQ-PCR turned negative after the blinatumomab regimen. Another two weeks of blinatumomab was given as bridge and then haploidentical HSCT was performed. Because his MRD by NGS IGH was 0.0311% before HSCT, the child received 3 cycles of blinatumomab and two prophylactic DLIs to prevent post-transplant relapse. During the treatment with blinatumomab and DLI, the child developed grade 1 cytokine release syndrome (CRS), without other severe adverse reactions such as neurotoxicity, hypoxemia, and hypotension.ConclusionIn this pediatric patient with high-risk KMT2A::USP2-positive ALL, sequential blinatumomab plus prophylactic DLI was well-tolerated and maintained sustained remission after HSCT. This case preliminary supports the combined regimen for post-transplant relapse prevention in high-risk patients. Given case report limitations, larger prospective trials are needed to verify its safety, efficacy and optimal dosing for widespread clinical use. Background Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Significant progress has been made based on risk-stratified treatment strategies for pediatric ALL, with the long-term overall survival rate now exceeding 90%. However, approximately 20% of children still develop treatment resistance or experience relapse after achieving initial complete remission (1, 2). Allogeneic hematopoietic stem cell transplantation (HSCT) serves as a pivotal therapeutic modality for refractory/relapsed ALL. Clinical studies have demonstrated that children with ALL undergoing HSCT after their first relapse achieve a long-term survival rate of approximately 50% (3). A large cohort study of 439 pediatric ALL revealed that the HSCT group had a significantly superior 5-year overall survival rate of 52.4% compared to the conventional chemotherapy group, with an event-free survival (EFS) rate of 51.7% (4). Despite its established role as a cornerstone intervention for improving long-term outcomes in refractory/relapsed ALL, post-transplant relapse remains a formidable clinical challenge (5). The risk of relapse after HSCT is associated with MRD status before transplantation. The FORUM trial revealed that pediatric patients with ALL who had positive minimal residual disease (MRD≥10-4) before HSCT had a 3-year relapse rate of 33%, which was significantly higher than the 20% observed in MRD-negative patients (6). Currently, MRD assessment comprises multiparameter flow cytometry (mFCM), quantitative polymerase chain reaction (qPCR), and next-generation sequencing of immunoglobulin (NGS-Ig) gene rearrangements. Studies have indicated that positive NGS-Ig MRD status is the independent predictor of post-transplant relapse. Specifically, the 2-year relapse rate was 0% with an OS of 96% in the pre-transplant NGS-Ig MRD negative group, whereas the positive group had a markedly elevated relapse rate with an OS of only 77% (7). Current strategies for preventing post-transplantation relapse in pediatric ALL encompass timely tapering or discontinuation of immunosuppressants, the use of targeted agents, prophylactic DLI, and early intervention guided by regular MRD monitoring. These approaches have evolved from reliance on conventional chemotherapy alone toward a multidimensional strategy integrating molecular monitoring, immunotherapy, targeted therapy, and cellular therapies (8–10). In recent years, immunotherapies and molecularly targeted treatments have achieved significant progress in managing refractory or relapsed ALL (10–12). Blinatumomab has demonstrated efficacy not only in efficiently eradicating MRD in cases with suboptimal responses to conventional chemotherapy or with relapsed/refractory disease, but also shows emerging potential as maintenance therapy following HSCT for high-risk ALL (13–16).A single-center phase II study (NCT02807883) reported that among 21 adult patients with high-risk B-ALL who received four cycles of blinatumomab maintenance post-HSCT, the 1-year OS rate was 85% (95% CI 61%-95%) and 1-year progression-free survival (PFS) rate was 71% (95% CI 47%-86%), with a favorable tolerability profile. With a median follow-up of 14.3 months, median OS and median PFS were not reached in this cohort; the cumulative incidence of relapse at 1 year was 29% (95% CI 11%-49%), and 1-year nonrelapse mortality (NRM) was 0% (17). However, the aforementioned evidence is primarily based on adult data, and published literature on the use of blinatumomab for post-transplant relapse prevention in the pediatric population is limited. Therefore, this article reports a case of a child with high-risk ALL who received blinatumomab combined with prophylactic DLI for relapse prophylaxis after HSCT, aiming to provide clinical insights and reference for hematologists and oncologists. Case presentation A 5-year-old boy presented to our hospital’s Department of Oral and Maxillofacial Surgery on February 2, 2023, with left eye swelling and spontaneous unilateral knee ecchymosis. Tissue biopsy revealed B-lymphoblastic lymphoma/leukemia, leading to his referral to our department on February 16, 2023. Physical examination revealed mild edema of the left upper eyelid and left cheek. No enlarged superficial lymph nodes were palpable throughout the body. The liver was palpable 4 cm below the costal margin with a medium consistency, and the spleen was palpable 2 cm below the costal margin with a firm consistency. Initial complete blood count showed a white blood cell count (WBC) of 17.97×109/L, neutrophils 2.70×109/L, hemoglobin 99 g/L, and platelets 139×109/L. Bone marrow smear demonstrated 63% blasts. Flow cytometry revealed 70.2% phenotypically abnormal immature B-lymphocytes, with an immunophenotype positive for HLA-DR, CD34, CD38, CD19, CD79a, CD56, IgVH, IgL, and TCRD. Chromosomal karyotype analysis showed 41∼46,XY, t(4;11) (q21;q23),der(16)t(1;16) (q21;q12),inc (4)/46,XY (16). Whole-exome sequencing and RNA sequencing (RNA-Seq) identified a KMT2A::USP2 fusion gene. Next-Generation Sequencing-Based Clonality Assessment of Ig Gene Rearrangements revealed significant clonality for IGH-SEQ1, IGH-SEQ2, IGK-SEQ3, and IGK-SEQ4, with clonal frequencies of 80%, 18.19%, 14.05%, and 6.63%, respectively. The patient had received no treatment prior to presentation at our department and had no relevant past medical history or family history of similar disorders. At initial diagnosis, the patient presented with an orbital mass. Sinus computed tomography (CT) revealed a lesion measuring 4.2×3.9×3.3 cm involving the left orbit. Histopathological biopsy confirmed B-lymphoblastic lymphoma/leukemia. Despite negative cerebrospinal fluid (CSF) cytology and flow cytometry, the patient was classified as central nervous system leukemia grade 3 (CNS3) due to the presence of impaired ocular mobility associated with orbital tumor infiltration. Based on comprehensive medical history and ancillary investigations, the patient was diagnosed with early pro-B cell ALL, characterized by the presence of the KMT2A::USP2 fusion gene. Treatment was initiated using the SCCLG-ALL-2016 protocol, which is registered with the Chinese Clinical Trial Registry (ChiCTR; https://www.chictr.org.cn/; Registration Number: ChiCTR2000030357). After induction, MRD by FCM remained positive at 0.26%, RQ-PCR of KMT2A::USP2 was 1.247%, and NGS-Ig (IGH-SEQ1 4.8511%, IGH-SEQ2 1.2922%) were all continuously positive. (Figure 1). Given the high-risk cytogenetic feature of the KMT2A::USP2 fusion and persistent MRD positivity after induction-consolidation chemotherapy, HSCT was indicated to mitigate relapse risk and improve long-term survival. Informed consent was obtained from the patient and his family for the publication of this case report. After the first Block consolidation chemotherapy, A 28-day course of blinatumomab was administered from May 31 to June 28, 2023, with dose escalation from 5 μg/m²/d for the initial 3 days to 15 μg/m²/d for the subsequent 25 days, after which the MRD level decreased to less than 0.01%. Another two-week course of blinatumomab was administered from July 5 to July 19, 2023, as bridging therapy to further eliminate MRD prior to HSCT, with an initial dose of 5 μg/m²/d for 1 day followed by 15 μg/m²/d for the next 13 days, combined with 7-day venetoclax at a total daily dose of 116 mg/m². And then, a total body irradiation (TBI)-based conditioning regimen was administered from July 19 to July 21, 2023. The TBI was delivered via anterior-posterior (AP) and posterior-anterior (PA) fields at a prescribed dose of 12 Gy in 6 fractions (2 Gy twice daily), with shielding of the right eye lens, bilateral lungs, kidneys, bladder, and testes. The conditioning regimen further consisted of Me-CCNU (250 mg/m²), thiotepa (TT, 10 mg/kg), anti-thymocyte globulin (ATG, 7 mg/kg), etoposide (VP16, 40 mg/kg), and cyclophosphamide (CTX, 120 mg/kg/day). Before transplantation, the patient exhibited normal ocular mobility. Pre-transplant cranial PET-MRI revealed no soft-tissue mass or increased metabolic activity in the maxillary sinus, consistent with Deauville score 1. In addition, CSF cytology showed no leukemic blasts, and CSF flow cytometry was negative. On July 27, 2023, the patient underwent transplantation with peripheral blood stem cells from a related donor (father, haploidentical, blood group O to O). The graft contained 8.3×108/kg mononuclear cells, with an infused CD34+ cell dose of 14.3×106/kg. Both neutrophil and platelet engraftment were achieved by day +13 post-transplantation (Figure 2). During the HSCT course, complications included engraftment syndrome, grade III oral mucositis, infectious fever, upper respiratory tract infection, and multiple electrolyte imbalances, all of which were ultimately resolved with appropriate management. Graft-versus-host disease (GVHD) prophylaxis included PTCy, short-course methotrexate (MTX), cyclosporine A (CsA), and mycophenolate mofetil (MMF). PTCy was given as a single dose of 35 mg/kg on day +3 after HSCT. MMF was discontinued on day +31 post-transplant, and CsA was tapered and stopped on day +89 post-transplant. The schema of therapy in this patient. Process of pretreatment and transplantation. In this case, the pediatric patient had persistently positive NGS-Ig prior to transplantation, placing him in a high-risk group for post-transplant relapse; thus, active measures should be taken for relapse prophylaxis. Therefore, immunosuppressive agents including cyclosporine were gradually tapered and discontinued around month +3. The first DLI, with a CD3+ cell dose of 8.9×105/kg, was administered on September 25, 2023(HSCT d+60). The first post-transplant cycle of blinatumomab was initiated on October 25, 2023 (HSCT d. +90; 5 µg/m²/day for 3 days, then 10 µg/m²/day for 3 days, followed by 15 µg/m²/day for 10 days). During this cycle, a second DLI (CD3+ cell dose approximately 5×106/kg) was given on November 3, 2023 (HSCT d+99; day 8 of blinatumomab). On the day following the second DLI, the patient developed a pruritic rash on the back, which resolved with antihistamine treatment. No other signs of graft-versus-host disease were observed, and the rash was considered likely related to the DLI. Subsequent maintenance cycles of blinatumomab were administered on December 25, 2023 (HSCT d+151; 5 µg/m²/day for 2 days, then 10 µg/m²/day for 1 day, followed by 15 µg/m²/day for 12 days) and February 26, 2024 (HSCT d+214; 5 µg/m²/day for 3 days, then 15 µg/m²/day for 11 days). Post-transplant interventions are shown in Figure 3. During blinatumomab treatment, the patient experienced grade 1 CRS, which was managed supportively and resolved. As shown in Figure 4, bone marrow MRD remained negative at all time-points when DLI or blinatumomab was administered. The post-transplant interventions. The trend of NGS IGH rearrangement. Dynamic changes of immune cell subsets and serum IgG levels after transplantation are summarized in Table 1. A decline in IgG levels was observed following blinatumomab administration. The proportion of Treg cells increased during each cycle of blinatumomab treatment and decreased after drug discontinuation. The variation trend of the CD4+/CD8+ T cell ratio was unpredictable in this case. Table 1Immune reconstitution indicators after HSCT.DateCD4+T cell (%)CD8+T cell (%)Treg (%)IgG (g/L)2023-07-27 HSCT 2023/8/2819.270.2-8.132023-09-25 DLI (1) 2023/9/25 pre-DLI9.381-7.15 2023/10/2310.471.9-5.862023-10-25 Blinatumomab (1) 2023/10/3015.6674.853.5–2023-11-03 DLI (2) 2023/11/617.768.67.784.33 2023/11/1019.156.69.04-2023-12-25 Blinatumomab (2) 2023/12/25 pre-Blinatumomab17.9761.914.263.05 2024/1/1027.8657.46.42.652024-02-26 Blinatumomab (3) 2024/2/26 pre-Blinatumomab25.8647.755.342.22 2024/3/1328.5658.047.12- 2024/4/253543.4-2.59 2024/7/2930.542.5-5.53 2025/1/2335.937.4-5.8 2025/7/3136.433-8.79 Immune reconstitution indicators after HSCT. To date, post-transplant monitoring shows sustained complete remission: bone marrow morphology is consistent with complete remission, MRD by FCM was negative, the quantitative levels of KMT2A::USP2 fusion gene and KDM6A mutation were 0%, and Ig-NGS MRD was below the detection limit. (<10-6, Figure 4). Serial post-transplant bone marrow chimerism monitoring demonstrated sustained full donor chimerism, with donor chimerism levels fluctuating between 99.44% and 99.82%. Regarding central nervous system leukemia, serial cranial MRI after transplantation showed no evidence of disease progression, and no deterioration of ocular function was observed. Monitoring of organ function in the child is detailed in Table 2. With organ shielding during TBI (as applied in the conditioning regimen), gonadal reserve was relatively preserved; renal and thyroid function remained within normal limits. Serial orbital MRI and pulmonary function tests showed no abnormalities, with no evidence of TBI-related organ damage. Tracking of growth and development is detailed in Figure 5. After the child underwent HSCT, the body weight was at the 50th percentile of the growth curve for children of the same age, and the height was approximately at the 25th percentile of the growth curve for children of the same age, with a stable growth trajectory. These findings suggest that physical development after transplantation maintained a normal growth rate, without obvious growth retardation or nutritional imbalance. Table 2Organ function indicators after HSCT.DateInhibinB (pg/ml)AMH (ng/ml)FSH (IU/L)LH (IU/L)T (ng/ml)TSH (uIU/mL)T3 (pmol/L)T4 (pmol/L)CREA (umol/L)eGFR (ml/min.1.73 m2)2023/12/263531.361.190.05<0.132.5394.7410.0623166.632024/7/261163.981.450.07<0.136.237.6110.0421190.842025/1/238977.480.950.04<0.132.8578.4611.7722187.152025/7/305092.031.140.05<0.133.3546.9312.0322189.97 Organ function indicators after HSCT. The growth and development status after HSCT. Discussion DLI is a critical intervention for managing post-HSCT relapse or refractory hematological malignancies. Its underlying mechanism involves harnessing the immune reactivity of donor-derived T cells to eradicate residual leukemic cells. Studies indicate that prophylactic or preemptive DLI following allogeneic HSCT for pediatric hematologic malignancies is associated with favorable 5-year event-free survival rates. However, the risk of GVHD correlates with the infused cell dose; patients receiving dose-escalation regimens show a trend toward reduced incidence of moderate-to-severe chronic GVHD (borderline significance, p=0.051) (18). The efficacy of DLI is influenced by multiple factors, including tumor burden, timing of relapse, donor T-cell predominance, and cell dose. DLI demonstrates more pronounced effects in settings of low tumor burden and early-stage relapse (19). In the present case, DLI was administered prophylactically while the patient was in sustained bone marrow remission. This approach aimed to leverage the significant anti-leukemic activity of DLI during the early post-transplant phase when tumor burden is minimal. Blinatumomab, a bispecific T-cell engager antibody, exerts its therapeutic effect by simultaneously binding to the CD19 antigen on B-ALL cells and the CD3 antigen on T cells. This dual binding effectively recruits and activates cytotoxic T lymphocytes, triggering a targeted immune response that leads to the elimination of leukemic cells. In the treatment of pediatric refractory or relapsed (R/R) ALL, its clinical utility is well-established and varies according to the phase of therapy in which it is applied. Prior to HSCT, blinatumomab serves as an effective bridging or consolidative therapy, creating a window for successful transplantation. In a phase I/II study (NCT01471782), blinatumomab administered at 15 µg/m²/day demonstrated a favorable tolerability profile in 49 children with R/R B-ALL. Among them, 39% achieved complete remission (CR) with single-agent therapy (20). The subsequent RIALTO expanded access study (NCT02187354) further confirmed its efficacy, reporting that 63% of pediatric patients achieved CR within the first two treatment cycles, with 83% of responders attaining MRD negativity (14, 21). Furthermore, two randomized trials (NCT02393859 and NCT02101853) indicated that blinatumomab, when used as consolidation therapy prior to allo-HSCT, significantly improved EFS in children with high-risk first-relapse B-ALL compared to conventional chemotherapy. It also improved RFS and OS in standard-risk patients (22, 23). In the present case, the patient exhibited persistently positive MRD by flow cytometry following high-risk induction, VDLD-CAM, and consolidation with BLOCK(1) chemotherapy. After receiving one cycle of blinatumomab, the patient achieved MRD negativity in the bone marrow, which successfully enabled bridging to HSCT. As a salvage therapy for post-transplant relapse, blinatumomab has demonstrated promising efficacy. A study involving 38 pediatric patients with post-HSCT relapse reported an overall response rate of 34% following blinatumomab treatment, with 24% achieving sustained molecular remission, thereby creating an opportunity for a second transplantation (24). Furthermore, preliminary data support its use for relapse prevention after transplantation. A single-center phase II study evaluating blinatumomab maintenance in post-transplant B-ALL patients (median age 30 years) showed a 1-year OS rate of 85% and a 1-year PFS rate of 71%, with a favorable tolerability profile (17). Similarly, a study in a pediatric post-transplant setting observed a relapse rate of 20% in patients receiving blinatumomab maintenance, which was significantly lower than the 31% rate in the control group without maintenance therapy (25). These findings suggest that post-transplant administration of blinatumomab can effectively control residual disease and reduce the risk of relapse. Both DLI and blinatumomab can be utilized for relapse prevention following transplantation in ALL. This raises the question of whether combining these two modalities could yield superior outcomes. In recent years, both blinatumomab and DLI have demonstrated potential as maintenance therapies to prevent relapse after HSCT. They are thought to improve long-term survival and quality of life by enhancing the patient’s immune response and reducing tumor burden (13, 17, 26). Blinatumomab functions by forming a lytic synapse between T cells and tumor cells, leading to tumor cell lysis and apoptosis. Based on this mechanism, we postulated that administering DLI on day +8 of a blinatumomab cycle might lead to a synergistic antitumor effect (27, 28). The infused donor lymphocytes from DLI can augment the host immune system. These cells may synergize with the blinatumomab-activated T cells, potentially enabling more effective recognition and clearance of residual leukemic cells. Concurrently, blinatumomab reduces tumor burden through direct T cell-mediated cytotoxicity, which may create a more favorable microenvironment for the efficacy of DLI. The effects of maintenance treatment with blinatumomab combined with DLI on post-transplant immune reconstitution remain poorly elucidated. Studies have demonstrated that immune reconstitution occurs gradually following HSCT. In the early post-transplant period, the proportion of CD4+ T cells remains low, while CD8+ T cells undergo dominant expansion, resulting in an inverted CD4/CD8 ratio (29). Based on the sequential immunotherapeutic strategy adopted in this case, DLI exogenously supplies mature functional T cells. On one hand, it facilitates the early expansion of donor-derived CD8+ cytotoxic T cells and lays the foundation for graft-versus-leukemia (GVL) effects. On the other hand, it optimizes the immune microenvironment and promotes CD4+ T cell reconstitution after transplantation. Meanwhile, blinatumomab sustains the cytotoxic activity of CD8+ T cells and reduces MRD, further constructing a favorable immune microenvironment to potentiate the GVL effect mediated by DLI. After two cycles of DLI treatment, the proportion of CD8+ T cells gradually declines alongside the progressive recovery of CD4+ T cells and eventually reaches a steady state, indicating satisfactory cellular immune reconstitution. In addition, the patient achieved sustained disease remission with low tumor burden after HSCT. No obvious proliferation of CD4+and CD8+ T cells was observed during blinatumomab administration, which is consistent with previous literature findings (30). Serum IgG levels decreased during combined treatment with DLI and blinatumomab. This phenomenon is attributed to targeted depletion of B cells and incomplete recovery of helper function of CD4+ T cells. Subsequent recovery of cellular immunity contributes to the gradual elevation of IgG levels, suggesting progressive restoration of humoral immune function. The proportion of regulatory T cells (Treg) is relatively low in the early post-transplant phase, which is consistent with the inherent delayed reconstitution characteristics of Treg cells (31). Two rounds of DLI markedly elevate Treg proportions, which is jointly induced by infused donor lymphocytes and endogenous compensatory proliferation. Elevated Treg cells can effectively suppress excessive activation of alloreactive T cells. The dynamic alteration pattern of Treg cells under blinatumomab treatment has not been fully clarified. In this case, Treg proportions increased during three courses of blinatumomab therapy and declined after drug withdrawal. The upregulation of Treg cells may restrain excessive inflammatory responses and protect hematopoietic and immune reconstitution. Notably, the absence of a remarkable reduction in Treg levels does not indicate DLI treatment failure. The gradual recovery of CD4+ T cells, restored CD4/CD8 ratio and late elevation of IgG collectively confirm favorable immune reconstitution. Further investigations with expanded case cohorts are required to explore the comprehensive impacts of combined blinatumomab and DLI therapy on immune reconstitution. Regarding safety, blinatumomab is associated with a relatively low incidence of adverse events and offers a more favorable safety profile compared to conventional chemotherapy (24). The standard treatment protocol recommends continuous infusion over four weeks per cycle. However, in our center, a modified administration strategy was employed when used post-HSCT. Following an initial slow dose escalation starting at 5 µg/m², a target dose of 15 µg/m² was administered via continuous infusion, with treatment cycles averaging 14 days. In this case, the patient developed grade 1 CRS manifesting as low-grade fever and localized rash during blinatumomab treatment, which resolved after symptomatic management with antipyretics and intensified local skin care. No blinatumomab-related neurotoxicity was observed; thus, prophylactic levetiracetam was not administered. Notably, no other severe adverse events including central nervous system abnormalities, hypoxemia or hypotension occurred, and such favorable tolerability may be attributed to the adopted dose-escalation strategy. Furthermore, the rash that developed during the second DLI in this case necessitated differentiation between an infusion-related reaction and DLI-induced GVHD. Consequently, DLI therapy requires careful balancing of the GVL effect against the risk of GVHD, with dose and schedule adjustments guided by individual treatment response. While immunosuppressants are routinely administered post-transplantation to prevent GVHD, they concurrently suppress donor T-cell activity, thereby potentially diminishing the GVL effect of DLI. Therefore, in this patient, immunosuppressive agents were gradually tapered and discontinued around month +3 post-transplantation. Additionally, DLI was omitted during the third post-transplant cycle of blinatumomab due to prior mild GVHD. Throughout the follow-up period, no clinical manifestations of GVHD were observed. The combined approach adopted in this case offers a feasible strategy for relapse prevention following transplantation. Future investigations into blinatumomab plus prophylactic DLI therapy should focus on elucidating the optimal sequence and timing of the combination, as well as its interaction with immunosuppressive agents. These aspects warrant validation in larger cohorts and more in-depth mechanistic exploration. Conclusions The combination of blinatumomab and prophylactic DLI appears to be a safe and potentially effective strategy for preventing relapse in acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation, representing a potential prophylactic option in the post-transplant setting. To date, the pediatric patient in this case has achieved sustained complete remission, resulting in improved survival outcomes.